Safety and side-effects of buprenorphine in the clinical management of heroin addiction

https://doi.org/10.1016/0376-8716(90)90078-SGet rights and content

Abstract

Sublingual buprenorphine (8 mg) was administered to heroin-dependent addicts daily for 18 days and continued from day 19 –day 36 either daily or on alternate days. Final data are reported on 18 subjects. The number of self-reported symptoms reviewed as potential adverse drug reactions ranged from 1 to 88 per participant. None was considered to be related definitely to the study medication, and there were no reporting differences between the two dosing regimens. Forty-five reactions were considered probably related to buprenorphine: sedation/drowsiness (three reports) and constipation (42 reports). It was concluded that these were anticipated drug effects rather than adverse reactions. Although some participants showed increases in serum aminotransferase levels, those increases could not be directly attributed to buprenorphine. We conclude that buprenorphine was well tolerated, but further study is needed in this population to delineate the possible attributable risk of the drug to hepatic dysfunction in this population.

References (40)

  • D.R. Jasinski et al.

    Sublingual versus subcutaneous buprenorphine in opiate abusers

    Clin. Pharmacol. Ther.

    (1989)
  • S.S.W. Seow et al.

    Buprenorphine: a new maintenance opiate?

    Med. J. Aust.

    (1986)
  • W.K. Bickel et al.

    A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts

    Clin. Pharmacol. Ther.

    (1988)
  • G. DeKlerk et al.

    Comparative study on the circulatory and respiratory effects of buprenorphine and methadone

    Acta. Anesth. Belg.

    (1981)
  • W.K. Bickel et al.

    Buprenorphine: dose related blockade of opioid challenge effects in opioid dependent humans

    J. Pharmacol. Exp. Ther.

    (1988)
  • R.E. Johnson et al.

    Use of buprenorphine in the treatment of opiate addiction. I: Physiologic and behavioral effects during a rapid dose induction

    Clin. Pharmacol. Ther.

    (1989)
  • P.J. Fudala et al.

    Use of buprenorhpine in the treatment of opiate addiction. II: Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal

    Clin. Pharmacol. Ther.

    (1990)
  • F.E. Karch et al.

    Adverse drug reactions, A critical review

    J. Am. Med. Assoc.

    (1975)
  • N.K. Mello et al.

    Buprenorphine effects on human heroin self-administration: an operant analysis

    J. Pharmacol. Exp. Ther.

    (1982)
  • R.G.D. Steel et al.

    Principles and Procedures of Statistics. A Biometrical Approach

    (1980)
  • Cited by (90)

    • “You get that craving and you go for a half-hour run”: Exploring the acceptability of exercise as an adjunct treatment for substance use disorder

      2021, Mental Health and Physical Activity
      Citation Excerpt :

      All four of these approaches have shown to be beneficial in the treatment of SUD (Farrell et al., 1994; Mattick, Breen, Kimber, & Davoli, 2014; Skinner, Lahmek, Pham, & Aubin, 2014; Srisurapanount & Jarusuraisin, 2005). However, side effects are associated with all pharmacological approaches for SUD (Kreek, 1973; Lange, Fudala, Dax, & Johnson, 1990; Malcolm, Olive, & Lechner, 2008; Srisurapanount & Jarusuraisin, 2005). Finally, in terms of the patient's perspective on integrating pharmacotherapy for AUD, there were concerns over the safety of the treatment, not wanting to substitute one substance for another, and believing their condition does not warrant pharmacological aid (Haley, Pinsker, Gerould, Wisdom, & Hagedorn, 2019).

    • Evidence of validity and reliability of the Opiate Dosage Adequacy Scale (ODAS) in a sample of heroin addicted patients in buprenorphine/naloxone maintenance treatment

      2018, Drug and Alcohol Dependence
      Citation Excerpt :

      Factor 2 (“Overmedication”) explains 24.9% of the variance and the ODAS items that load onto this factor are precisely those that measure this phenomenon. If symptoms of opioid blockade, OWS, and craving (items 2–5) can be considered “classic” indicators of dose adequacy (Amass et al., 1994; Bickel et al., 1988; Fudala et al., 1990, 2003; Ling et al., 1998, 2005; Walsh et al., 1995) and the continued use of heroin (item 1) can be considered an indicator of dose inadequacy (Hillhouse et al., 2011; Northrup et al., 2015; Heikman et al., 2017), then we can consider avoidance of overmedication (item 6) as an indicator of “good practices” (Lange et al., 1990). In our study, 17.8% of patients with buprenorphine doses classified as “inadequate” had significant symptoms of overmedication.

    • Naltrexone-facilitated buprenorphine discontinuation: A feasibility trial

      2015, Journal of Substance Abuse Treatment
      Citation Excerpt :

      Maintenance treatment with buprenorphine (often in combination with naloxone, as Suboxone®, to preclude inappropriate use) is an effective and increasingly popular approach to opioid dependence, with retention rates found to be as high as 50% at 6 months (Mattick, Kimber, Breen, & Davoli, 2008). Buprenorphine is a partial μ-opioid agonist and k-antagonist that works to ameliorate withdrawal phenomena and opioid craving, as well as attenuate the effects of co-administered opioids (Comer, Walker, & Collins, 2005; Lange, Fudala, Dax, et al., 1990; Orman & Keating, 2009). As with methadone, however, there is limited information about when or how buprenorphine can be safely discontinued once individuals achieve sustained full remission.

    • Perioperative analgesia and challenges in the drug-addicted and drug-dependent patient

      2014, Best Practice and Research: Clinical Anaesthesiology
    View all citing articles on Scopus
    View full text